2021
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
Park KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V, Sharma P, Pusztai L, Shen C, Partridge A, Thompson A. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Research And Treatment 2021, 188: 249-258. PMID: 33651271, PMCID: PMC7921279, DOI: 10.1007/s10549-021-06153-3.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionNeoadjuvant endocrine therapyMedical oncologistsRadiation oncologistsOmission of ALNDEstrogen positive breast cancer patientsPositive breast cancer patientsEarly-stage breast cancerEndocrine therapy useMetastatic axillary diseaseLymph node dissectionBreast cancer patientsMultidisciplinary tumor boardStage breast cancerClinical trial organizationsPercent of practicesUS medical oncologistsCOVID-19 pandemicPre-pandemic timesRegional COVID-19 casesAxillary diseaseMicrometastatic nodesSurgery 2Endocrine therapyLocoregional management
2020
A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Adams E, Lustberg M, Jin Y, Li Y, Sparreboom A, Hu S. A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer. Journal Of Clinical Oncology 2020, 38: tps12128-tps12128. DOI: 10.1200/jco.2020.38.15_suppl.tps12128.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel infusionFree survivalPeripheral neuropathyBreast cancerPaclitaxel-induced peripheral neuropathyBreast cancer stage IEarly-stage breast cancerGrade 2 neuropathyPhase Ib studyPhase II doseDisease-free survivalCancer stage IStage breast cancerBreast cancer therapyTyrosine kinase inhibitorsQuality of lifeOrganic anion transportingOATP1B1 inhibitionOral nilotinibWeekly paclitaxelPaclitaxel dosePaclitaxel therapyOverall survivalWeekly doses
2018
Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women
Foy K, Fisher J, Lustberg M, Gray D, DeGraffinreid C, Paskett E. Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women. Npj Breast Cancer 2018, 4: 7. PMID: 29582015, PMCID: PMC5861087, DOI: 10.1038/s41523-018-0059-5.Peer-Reviewed Original ResearchJames Cancer HospitalAA womenBreast cancerTumor characteristicsWhite womenCancer HospitalArthur G. James Cancer HospitalHigher breast cancer death rateBreast cancer tumor characteristicsCox proportional hazards regressionProgression-free survival probabilityBreast cancer death ratesLate-stage breast cancerLikelihood ratio chi-square testProportional hazards regressionStage breast cancerOverall survival probabilityCancer death ratesOnset of treatmentCurrent tobacco useChi-square testAfrican American womenPrompt treatmentCancer RegistryHazards regression
2015
Impact of breast cancer treatment on body mass index (BMI) over time.
Reinbolt R, Pan X, Wandell K, Pilarski R, Layman R, Mrozek E, Ramaswamy B, Wesolowski R, Lustberg M. Impact of breast cancer treatment on body mass index (BMI) over time. Journal Of Clinical Oncology 2015, 33: 94-94. DOI: 10.1200/jco.2015.33.28_suppl.94.Peer-Reviewed Original ResearchBody mass indexBreast cancer patientsEndocrine therapyAromatase inhibitorsWeight gainBMI changeCancer patientsEarly placebo-controlled trialsInitial body mass indexEarly-stage breast cancerHigher body mass indexBody mass index (BMI) changeBreast cancer patient cohortsPlacebo-controlled trialRetrospective chart reviewStage breast cancerBreast cancer treatmentCancer patient cohortsBreast cancer therapyQuality of lifeDifferent treatment groupsAI therapyChart reviewTreatment initiationMass indexHealthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors
Arnold K, Andridge R, Logan A, Yee L, Lustberg M, Orchard T. Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.lb267.Peer-Reviewed Original ResearchHealthy Eating Index 2010Breast cancer survivorsTumor necrosis factor alpha receptor 2Cancer survivorsHEI scoresDiet qualityInflammatory markersIL-17IL-6Breast cancerTNFR-2Randomized placebo-controlled pilot studyOmega-3 Fatty Acid SupplementationPlacebo-controlled pilot studyEarly-stage breast cancerHealthy Eating Index scoreHealthier diet qualityStage breast cancerLower IL-6Fatty acid supplementationAromatase inhibitor treatmentAI therapyChemotherapy statusPrior chemotherapyPostmenopausal womenNeoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials
Hicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.Peer-Reviewed Original ResearchConceptsAddition of lapatinibHER2-positive breast cancerNeoadjuvant chemotherapyBreast cancerLymph nodesClinical trialsEarly-stage HER2-positive breast cancerSan Antonio Breast Cancer SymposiumPathologic complete response rateEarly-stage breast cancerResidual invasive cancerResidual invasive carcinomaComplete response rateOperable breast cancerAxillary lymph nodesPathologic complete responseProspective clinical trialsStage breast cancerRates of pCRDual HER2NAC armProspective RCTsCancer SymposiumPCR rateComplete response